Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: RESULTS: The mean daily glucose level decreased from 9.2 +/- 0.2 to 8.4 +/- 0.2 mmol/l (P = 0.001) and HbA1c decreased from 8.8 +/- 0.1 to 8.0 +/- 0.1% (P < 0.001) (mean +/- SD). The number of daily NPH injections increased from 1.4 +/- 0.1 at baseline to 3.1 +/- 0.1 at the end of the study. Total daily insulin dose increased by 3 U (7%) because of an 8-U (43%) rise in basal insulin, whereas premeal insulin dose decreased by 5 U (20%). The number of hypoglycemic episodes did not change during the study. Of the patients, 86% considered insulin lispro equal or better than human regular insulin. CONCLUSIONS:
|
Authors | P Ebeling, P A Jansson, U Smith, C Lalli, G B Bolli, V A Koivisto |
Journal | Diabetes care
(Diabetes Care)
Vol. 20
Issue 8
Pg. 1287-9
(Aug 1997)
ISSN: 0149-5992 [Print] United States |
PMID | 9250455
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Insulin
- Insulin Lispro
|
Topics |
- Adolescent
- Adult
- Blood Glucose
(metabolism)
- Diabetes Mellitus, Type 1
(blood, drug therapy)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Fasting
(blood)
- Female
- Glycated Hemoglobin
(metabolism)
- Humans
- Hypoglycemia
(blood)
- Hypoglycemic Agents
(administration & dosage, therapeutic use)
- Insulin
(administration & dosage, analogs & derivatives, therapeutic use)
- Insulin Lispro
- Male
- Middle Aged
- Postprandial Period
- Surveys and Questionnaires
|